43 results about "Infectious bronchitis virus" patented technology

The invention belongs to the field of veterinary drugs, and relates to an avian infectious bronchitis virus antigen recombinant protein S-Trimer and a subunit vaccine thereof. The invention provides an avian infectious bronchitis virus antigen recombinant protein S-Trimer. The amino acid sequence of the antigen recombinant protein S-Trimer is as shown in SEQ ID No. 4. The invention provides an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer. The invention provides a chicken infectious bronchitis virus subunit vaccine. The subunit vaccine comprises a pharmaceutically acceptable carrier and an immune dose of the chicken infectious bronchitis virus antigen. The vaccine is high in safety, good in immunogenicity and stable in batches, and can provide complete protection for attacking the infectious bronchitis virus.

The invention provides an infectious bronchitis virus subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering vaccines. According to the chicken infectious bronchitis virus mutant protein disclosed by the invention, the amino acid sequence of the mutant protein is shown as SEQ ID NO.5. According to the avian infectious bronchitis virus subunit vaccine containing the recombinant avian infectious bronchitis virus mutant protein Kozak-IgKsp-IBV-M41-S-core-6His as an effective component, the glycosylation level of the vaccine is relatively high, the expression level is relatively stable, the virus return risk of a live vaccine does not exist, the safety is high, large-scale industrial preparation can be achieved, and the vaccine has good application prospects. The cost is low.

The present application belongs to the field of veterinary drugs, and provides a recombinant protein S-Trimer of an infectious bronchitis virus antigen and a subunit vaccine therefor. Provided in the present application is a recombinant protein S-Trimer of an infectious bronchitis virus antigen, wherein the recombinant protein S-Trimer of the antigen has an amino acid sequence as set forth in SEQ ID No. 4. Also provided in the present application is an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer described above. The present application provides a subunit vaccine for an infectious bronchitis virus, wherein the subunit vaccine comprises a pharmaceutically acceptable carrier and an immunogenic amount of the infectious bronchitis virus antigen.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

The invention provides a QX type avian infectious bronchitis virus mRNA vaccine and application thereof. The gene sequence of the mRNA vaccine molecule is shown as SEQ ID NO.9 or SEQ ID NO.13. The invention also provides a preparation method of the QX type avian infectious bronchitis virus mRNA vaccine. The preparation method of the QX-type avian infectious bronchitis virus mRNA vaccine molecule provided by the invention is simple to operate, preparation can be performed only by knowing a gene sequence, and compared with an inactivated vaccine, the production price is low, and the dosage is small; compared with attenuated live vaccines, the vaccine is short in production period and safe.

The invention relates to a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination and a kit for an infectious bronchitis virus. The invention belongs to the field of biology, and discloses a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination for GI-13 / GI-19 / GVI-1 typing and general detection of an infectious bronchitis virus. Comprising a first primer probe combination for distinguishing an infectious bronchitis virus from other viruses, a second primer probe combination for identifying a GI-13 type infectious bronchitis virus, and a third primer probe combination for identifying a GI-19 type infectious bronchitis virus, and the fourth primer probe combination is used for identifying the GVI-1 type avian infectious bronchitis virus. The PCR primer probe combination is suitable for an RT-qPCR detection system, and can be used for effectively distinguishing GI-19, GI-13 and GVI-1 type IBV viruses; meanwhile, the invention further discloses a kit.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

The application provides a general avian infectious bronchitis virus whole genome deep sequencing method and application. The method realizes efficient amplification of long fragments of whole genomes of different genotype IBV epidemic strains by designing and applying a set of combinations containing 24 pairs of specific primers. The specific sequences of the primer combinations are shown in SEQ NO:1 to SEQ NO:48. Compared with a traditional sequencing method, the application significantly reduces the sequencing cost. Only two PCR reactions are needed, and more than 27 kb of IBV full-length genome sequence can be successfully obtained, which provides a more economical and efficient solution for IBV related scientific research and molecular epidemiology monitoring, and helps to promote the development of related field scientific research.

DEPCT64 This invention relates to 4 / 91IBV (Infectious Bronchitis Virus) which is coded for... Heterologous S (spike) protein or fragments thereof; furthermore, this invention also... This is related to the components that elicit an immune response, which include the aforementioned 4 / 91IBV. Process the code for heterologous S (spike) protein or fragments thereof. This invention also relates to a method for immunizing targets, which includes: Providing the target with an element that induces an immune response to this invention. Furthermore, this invention relates to methods for treating or preventing clinical symptoms caused by IBV. The necessary objectives involve a method of providing the target with the required quantity. The therapeutic efficacy of the immune response-inducing components according to this invention. -----------------------------------------------------------

Disclosed in the present invention are a dimethylphosphoryl substituted compound, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention can target a host eIF2α kinase, eIF2α phosphorylation and protein synthesis. The compound of the present invention has great biological activity for treating breast cancer. Particularly, compound SIPI-27 and compound SIPI-28 of the present invention has inhibitory activity against breast cancer significantly superior to that of the control compounds BTdCPU and neratinib; and / or the compound of the present invention also has biological activity against coronaviruses and / or orthopoxviruses, in particular, compound SIPI-25 of the present invention has broad-spectrum anti-coronavirus activity against porcine epidemic diarrhea virus (PEDV), mouse hepatitis virus (MHV), infectious bronchitis virus (IBV) and porcine deltacoronavirus (PDCoV), and also has activity against the Taterapox virus (TTV) orthopoxvirus.

The invention belongs to the technical field of genetic engineering, and particularly relates to an mRNA vaccine based on an infectious bronchitis virus S protein RBD segment. The active ingredient of the vaccine provided by the invention is mRNA (messenger ribonucleic acid) as shown in SEQ ID NO.1 or SEQ ID NO.2. Specific DNA molecules are obtained through a series of sequence design and sequence optimization, specific recombinant plasmids are further obtained, the recombinant plasmids are linearized and recycled and then transcribed into mRNA in vitro, modification such as capping and tailing is carried out, purification is carried out, then mRNA preparation is completed, the mRNA and lipid nanoparticles are mixed and then self-assembled into the lipid nanoparticles loaded with IBV S1-RBD mRNA, and the IBV S1-RBD mRNA lipid nanoparticles loaded with IBV S1-RBD mRNA are obtained. As a novel vaccine, the vaccine can provide a complete protection effect on SPF chickens infected by IBV, and has a good application prospect.

The invention discloses a primer probe composition for detecting AIV, NDV virulent strains and IBV, a kit and application, and belongs to the technical field of fluorescence detection. The sequence of the primer probe combination is shown as SEQ ID NO.1-SEQ ID NO.9, the primer probe combination comprises a primer pair and a probe for detecting the avian influenza virus, the Newcastle disease virus virulent strain and the avian infectious bronchitis virus, and the primer probe combination can be used for detecting and distinguishing all subtypes of the avian influenza virus and the Newcastle disease virus virulent strain and different genotypes of the avian infectious bronchitis viruses. The kit is high in specificity and sensitivity, does not have cross reaction with other common viruses, and is high in detection sensitivity, and the minimum detectable quantity of the three viruses is 0.8 copy, so that the specific, sensitive and rapid detection of AIV, NDV and IBV can be realized, and the defects of the conventional detection technology are overcome. The method has important practical significance on timely blocking epidemic situation propagation, reducing breeding loss, guaranteeing public health safety and the like.

This invention discloses a primer composition, kit, and application for avian pathogens. The primer composition comprises a crRNA with the sequence shown in SEQ ID NO: 1, an RT-RAA upstream primer with the sequence shown in SEQ ID NO: 2, and an RT-RAA downstream primer with the nucleotide sequence shown in SEQ ID NO: 3. It may also include a fluorescent probe with the sequence TTTTT. This primer composition can be used for the detection of avian infectious bronchitis virus, exhibiting high specificity and no cross-reactivity with common avian viruses such as avian influenza virus, Newcastle disease virus, and infectious laryngotracheitis virus. Furthermore, the primer composition has high sensitivity, with a detection limit as low as 4.25 × 10⁻⁶. 2 The primer composition exhibits high copy number / μL, good reproducibility, and stable results. It is suitable for single-tube isothermal nucleic acid amplification detection, offering mild reaction conditions and significantly reduced detection time, demonstrating excellent industrial application value.

The invention relates to the technical field of virology, in particular to an infectious bronchitis virus CK / CH / FJ-B3 / 2023 capable of causing immunosuppression, and the preservation number of the infectious bronchitis virus CK / CH / FJ-B3 / 2023 is CCTCC (China Center For Type Culture Collection) NO: V202563. The CK / CH / FJ-B3 / 2023 is separated from an immune tissue bursal disease of a chicken flock immunized with an infectious bronchitis vaccine, and is separated and purified to identify that the pathogen is an infectious bronchitis virus, and the genotype is GI-19. CK / CH / FJ-B3 / 2023 infected 7-day-old SPF chicken can cause atrophy and pathological injury of bursa of Fabricius besides typical respiratory tract symptoms, and the bursa of Fabricius can expel toxins for a long time and cause immunosuppression. The CK / CH / FJ-B3 / 2023 can be used for researching the pathogenesis of immune injury caused by the infectious bronchitis virus, can be used for evaluating the effectiveness of the existing chicken vaccine, and can also be used as a candidate vaccine strain of an inactivated vaccine. The CK / CH / FJ-B3 / 2023 has important significance in the prevention and control of epidemic diseases in clinical culture.

The invention relates to the technical field of gene engineering, in particular to an avian infectious bronchitis virus system based on double reporter genes and application thereof. According to the avian infectious bronchitis virus system based on the double reporter genes, real-time monitoring of IBV infection and replication can be achieved, the detection sensitivity and specificity are improved, meanwhile, experimental operation is simplified, and cost is reduced. The system can be used for various applications including but not limited to virus susceptible cell testing, virus entry mechanism research, antiviral drug screening, vaccine and neutralizing antibody effect evaluation, virus intrusion inhibitor evaluation and influence research of virus variation on infectivity. The system and the method provided by the invention provide a new tool for research and prevention and control of IBV and other enveloped viruses, and have important scientific and practical application values.

The present invention discloses a rapid detection kit for avian infectious bronchitis virus based on the CRISPR-Cas12a system, belonging to the technical field of detection reagents. The rapid detection kit for avian infectious bronchitis virus based on the CRISPR-Cas12a system disclosed by the present invention includes a fluorescent DNA reporter molecule and / or a lateral flow strip DNA reporter molecule, a crRNA, and upstream and downstream primers for isothermal amplification. The present invention has successfully established a rapid detection kit for IBV nucleic acid based on the CRISPR-Cas12a system, realizing rapid, sensitive and specific detection of IBV nucleic acid.

This invention discloses a chicken infectious bronchitis virus (IBBV) nanoparticle, its preparation method, and its application, belonging to the field of poultry vaccine technology. The nanoparticles are formed by the self-assembly of an SRBD-SpyTag fusion protein and a Ferritin-SpyCatcher fusion protein via a SpyTag / SpyCatcher covalent linkage system. The SRBD-SpyTag fusion protein is formed by fusing a SpyTag sequence to the N-terminus or C-terminus of the S1 protein receptor-binding domain of IBV. The nanovaccine prepared from these nanoparticles exhibits high safety, rapid antigen module replacement, and is suitable for preventing IBV infection. The technical solution of this invention has advantages such as structural stability, strong immunogenicity, and rapid iteration, providing a novel vaccine solution for poultry disease control.

The invention relates to the technical field of molecular biology detection, in particular to an MALDI-TOF MS (matrix-assisted laser desorption / ionization-time of flight mass spectrometry) detection method for simultaneously detecting avian influenza virus (AIV), Newcastle disease virus (NDV), avian infectious laryngotracheitis virus (ILTV), avian infectious bronchitis virus (IBV), fowl pox virus (FPV), fowl adenovirus (FAdV) and fowl metapneumosis (AMPV), and simultaneously can perform preliminary typing on the AIV. The MALDI-TOF MS-based detection method for multiple detection of the poultry epidemic disease viruses has the characteristics of high sensitivity, high specificity, high flux, good repeatability and high accuracy, and can be used for qualitatively detecting three types of subtype viruses of the seven viruses and the avian influenza virus (AIV) in an actual sample. The invention provides a novel and reliable technical method for trace early warning and monitoring of early infection of ten poultry epidemic disease viruses, differential diagnosis of other common viruses, research of propagation rules of the viruses, epidemiological risk assessment and other systematic applications.

This invention relates to the field of biotechnology, specifically disclosing a detection element, kit, and detection method for detecting infectious bronchitis virus (IBV) in chickens. The detection element is a Toehold Switch element, which is an S4-3 element and / or an S3 element; the nucleotide sequence of the S4-3 element is shown in SEQ ID NO: 1; the nucleotide sequence of the S3 element is shown in SEQ ID NO: 2. The detection element of this invention features high sensitivity and strong specificity, enabling the differentiation of three IBV strains—P65, MH20, and H120—at a single-base resolution.

The invention provides a primer and probe composition for typing detection of an infectious bronchitis virus. The composition is used for detecting genotypes of 4 / 91, TC07-2, LDT3, QX, LSC-99I and TW. The invention also provides a detection kit containing the primer and probe composition and a detection method. According to the invention, the detection of six genotypes is integrated into only two reaction tubes, the reaction steps are obviously reduced, the flux is improved, and a great leap is realized in multiple detection capability and detection efficiency, so that the kit is suitable for large-scale clinical screening and epidemiological investigation. The invention provides an unprecedented convenient and accurate tool for the diagnosis of complex clinical mixed infection by effectively identifying and combining the mixed infection of a plurality of genotypes through one-time reaction.

The invention relates to the technical field of biology, in particular to application of a G3BP1 gene as a target spot in screening of drugs for inhibiting IBV (infectious bronchitis virus) replication, experimental results show that when G3BP1 in cells is deleted, the IBV replication ability is enhanced, it is prompted that G3BP1 possibly has an inhibiting effect on IBV replication, the expression level of G3BP1 is remarkably and negatively correlated with the IBV replication ability, and the G3BP1 gene can be used as a target spot in screening of drugs for inhibiting IBV replication. EGCG can effectively inhibit duplication of IBV in Vero cells by up-regulating expression of a host limiting factor G3BP1, and after infection, administration and preventive administration both show a remarkable antiviral effect. The EGCG has the best excitation effect on G3BP1 and the most obvious inhibition effect on IBV intracellular replication, and the EGCG can effectively reverse IBV infection induced stress particle formation inhibition caused by G3BP1 knock-down.

Provided herein are non-naturally occurring, broadly reactive antigens derived from influenza viruses or avian infectious bronchitis virus (IBV) that are immunogenic and capable of eliciting a broadly reactive immune response, e.g., a broadly reactive neutralizing antibody response, directed against influenza virus antigens or IBV antigens following introduction into a subject. Also provided are non-naturally, broadly reactive immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a human or non-human subject by administering the immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens comprise broadly reactive hemagglutinin (HA) protein antigens of influenza virus strains, such as H1, H2, H3, H5, or H7, or of IBV. The immunogens also comprise broadly reactive viral neuraminidase (NA) protein antigens.

The invention provides a cDNA (complementary deoxyribonucleic acid) clone plasmid of an avian infectious bronchitis virus (IBV) for expressing secretory luciferase as well as a virus strain and a vaccine obtained by rescuing, and belongs to the technical field of biological medicines. The invention provides a construction method of cDNA (complementary deoxyribonucleic acid) clone plasmids of IBV (infectious bursal virus), which is completed by a one-step method based on yeast homologous recombination in a segmented amplification mode. The IBV infectious cDNA clone constructed by the method has good stability, an IBV genome can be transformed on a gene level by directly utilizing in-vitro homologous recombination, and the efficiency of constructing a recombinant virus is improved. According to the invention, a non-essential gene of the infectious cDNA clone is replaced by a Gluc reporter gene, and the obtained infectious cDNA clone directly transfects mammalian cells to rescue recombinant viruses. The recombinant virus is constructed through a virus rescue method, the growth characteristic of the recombinant virus is basically consistent with that of a parent virus, and genetic stability is kept.

The invention discloses a primer probe composition for detecting H9 subtype AIV, NDV and IBV, a kit and application, and belongs to the technical field of fluorescence detection. The sequence of the primer probe combination is shown as SEQ ID NO.1-SEQ ID NO.9, the primer probe combination comprises a primer pair and a probe for detecting the H9 subtype avian influenza virus, the Newcastle disease virus and the infectious bronchitis virus, can detect and distinguish epidemic H9 viruses of different branches, NDV of different genotypes and IBV of different genotypes, does not have cross reaction with other common viruses, and can be used for detecting and distinguishing the H9 viruses of different branches, the NDV of different genotypes and the IBV of different genotypes. The detection sensitivity is high, and the minimum detectable quantity of the three viruses is 0.8 copy, so that the specific, sensitive and rapid detection of H9, NDV and IBV can be realized, and the defects of the existing traditional detection technology are overcome. The method has important practical significance on timely blocking epidemic situation propagation, reducing breeding loss, guaranteeing public health safety and the like.

The invention relates to the technical field of biology, in particular to application of epigallocatechin gallate in preparation of a medicine for inhibiting infectious bronchitis virus (IBV) replication, and experimental results show that EGCG can effectively inhibit IBV replication in Vero cells by up-regulating expression of a host limiting factor G3BP1, so that the effect of inhibiting IBV replication is achieved. And after infection, administration and preventive administration both show an obvious antiviral effect. The EGCG has the best excitation effect on G3BP1 and the most obvious inhibition effect on IBV intracellular replication, and the EGCG can effectively reverse IBV infection induced stress particle formation inhibition caused by G3BP1 knock-down.

The invention provides an avian infectious bronchitis virus color visualization RAA rapid detection method, and relates to the technical field of veterinary diagnosis, and the method comprises the following steps: sample collection and treatment: collecting disease material samples representing respiratory tract symptoms, renal lesions or clinical symptoms of egg drop, extracting the samples, and carrying out sample treatment; carrying out nucleic acid extraction and reverse transcription, and carrying out RNA extraction and cDNA synthesis; carrying out conventional PCR detection; constructing a positive plasmid; the method has the advantages of rapidness, sensitivity, specificity, simplicity, convenience, low cost and the like, is suitable for rapid screening of the IBV in places with limited conditions, such as grassroots farms and veterinary stations, can be matched with laboratory nucleic acid electrophoresis verification to realize effective connection of primary screening and confirmation, and provides a new technical means for early discovery of the IBV and prevention and control of epidemic diseases.

The invention relates to the field of preparation of poultry vaccines, in particular to a vaccine composition for resisting Newcastle disease, infectious bronchitis and avian influenza. 5 to 15 parts of vitamin E; 2 to 10 parts of levamisole; 1-10 parts of a divalent inorganic salt; 1-5 parts of a complexing agent; 20-40 parts of a first bacterial liquid containing inactivated avian influenza virus; 20-30 parts of a second bacterial liquid containing inactivated infectious bronchitis virus; 10-30 parts of a third bacterial liquid containing inactivated Newcastle disease virus; 1 to 3 parts of aluminum stearate; and 10 to 15 parts of an oil phase. The vaccine prepared by the invention does not generate any adverse reaction to chickens, is high in experimental safety, and can induce high-level neutralizing antibodies in immunized chickens, which indicates that the immunized chickens can effectively resist virus attacks of Newcastle disease virus, avian influenza and infectious bronchitis virus.

The invention discloses a dimethyl phosphoryl substituted compound as well as a preparation method, a pharmaceutical composition and application thereof. The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound provided by the invention can target host eIF2alpha kinase, eIF2alpha phosphorylation and protein synthesis. The compound provided by the invention has excellent biological activity for treating breast cancer. Particularly, the inhibitory activity of the compound SIPI-27 and the compound SIPI-28 on the breast cancer is obviously superior to that of contrast compounds BTdCPU and neratinib; and / or the compound provided by the invention still has biological activity of resisting coronavirus and / or orthopoxvirus, and particularly, the compound SIPI-25 provided by the invention has broad-spectrum anti-coronavirus activity of resisting porcine epidemic diarrhea virus (PEDV), mouse hepatitis virus (MHV), infectious bronchitis virus (IBV) and porcine delta coronavirus (PDCoV), and also has anti-orthopoxvirus (TTV) activity.

The invention discloses a traditional Chinese medicine composition for preventing and treating exogenous wind-heat syndrome of livestock and poultry and application thereof, and belongs to the technical field of traditional Chinese veterinary medicines. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 60 to 100 parts of radix isatidis, 20 to 60 parts of gypsum, 20 to 60 parts of rhizoma phragmitis, 10 to 40 parts of radix rehmanniae, 10 to 30 parts of radix curcumae, 10 to 30 parts of rhizoma anemarrhenae, 10 to 30 parts of rhizoma acori graminei, 10 to 30 parts of herba pogostemonis and 15 to 50 parts of fructus forsythiae. The composition disclosed by the invention can be used for effectively treating exogenous wind-heat syndrome of livestock or poultry caused by infection of viruses such as chicken infectious bronchitis virus, avian influenza virus and swine influenza virus and respiratory tract symptoms caused by the exogenous wind-heat syndrome, and the resistance reducing and replacing effects are obvious.

The present invention relates, among other things, to an IBV (infectious bronchitis virus) deposited in the IZSLER BVR with accession number DPS RE RSCIC 16, any IBV descendant thereof, and any IBV having all the identifying characteristics of the deposited IBV. Furthermore, the present invention relates to an immunogenic composition comprising said deposited IBV.